Trioxane thioacetal monomers and dimers and methods of use thereof
AssigneeThe Johns Hopkins University
InventorsGary H. Posner, Alexander M. Jacobine, Rachel D. Slack, Jennifer R. Mazzone
Life of this patent
Estimating the term…
Abstract
Monomeric and dimeric trioxane thioacetals and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.
Claims20
A compound of Formula (I):
- wherein:
- R1 is —(CH2)n—O—R2a or —(CH2)n-1—C(═O)—R2b, wherein n is an integer from 2 to 11;
- and
- R2a is selected from the group consisting of H;
- —CH2C≡CH;
- —CH2—C(═CH2)R3, wherein R3 is halogen;
- —CH2—R4, wherein R4 is selected from the group consisting of:
- wherein R3 is as defined above;
- and —(C═X1)—R5;
- wherein X1 is O or S;
- and R5 is selected from the group consisting of substituted or unsubstituted alkyl, alkoxyl, substituted or unsubstituted aryl, —SR6, —NR6R7;
- wherein R6 and R7 are each selected from the group consisting of H, substituted or unsubstituted alkyl;
- and
- R2b is selected from the group consisting of hydroxyl;
- substituted or unsubstituted alkoxyl;
- substituted or unsubstituted aryloxyl;
- and —NR6R7, wherein R6 and R7 are as defined above;
- under the proviso that if R2b is hydroxyl, n cannot be 3;
- or an enantiomer, diastereomer, racemate or pharmaceutically acceptable salt, prodrug, or solvate thereof.
A compound of Formula (II):
- wherein:
- m and n can be the same or different and are each independently an integer selected from 3 or 6;
- or
- an enantiomer, diastereomer, racemate or pharmaceutically acceptable salt, prodrug, or solvate thereof.
A compound of Formula (III):
- wherein:
- each n is an integer independently selected from the group consisting of 3 and 6;
- L is a linking group selected from the group consisting of:
- or an enantiomer, diastereomer, racemate or pharmaceutically acceptable salt, prodrug, or solvate thereof.
A compound of Formula (IV):
- wherein:
- each n is an integer independently selected from the group consisting of 3 and 6;
- L is a linking group selected from the group consisting of:
- wherein:
- m is an integer from 2 to 8;
- R is selected from the group consisting of alkyl, cycloalkyl, heteroalkyl, aryl, and heteroaryl, each of which can be substituted or unsubstituted;
- or
- an enantiomer, diastereomer, racemate or pharmaceutically acceptable salt, prodrug, or solvate thereof.
A compound of Formula (V):
- wherein:
- each n is an integer independently selected from the group consisting of 3 and 6;
- L is a linking group selected from the group consisting of:
- wherein:
- m is an integer from 2 to 8;
- R is selected from the group consisting of alkyl, cycloalkyl, heteroalkyl, aryl, and heteroaryl, each of which can be substituted or unsubstituted;
- or
- an enantiomer, diastereomer, racemate or pharmaceutically acceptable salt, prodrug, or solvate thereof.
A method for preventing, controlling or treating an infectious disease in a subject in need of such treatment, the method comprising administering to the subject a therapeutically-effective amount of a compound of Formula (I-V) or an enantiomer, diastereomer, racemate or pharmaceutically acceptable salt, prodrug, or solvate thereof.
A method for treating a psychiatric disorder associated with a toxoplasma infection in a subject in need of treatment thereof, the method comprising administering to the subject a therapeutically-effective amount of a compound of Formula (I-V) or an enantiomer, diastereomer, racemate or pharmaceutically acceptable salt, prodrug, or solvate thereof.
A method for treating cancer in a subject in need of treatment thereof, the method comprising administering to the subject a therapeutically-effective amount of a compound of Formula (I-V).
Dependencies are inferred from the claim text.